期刊文献+

胸水细胞块EGFR基因突变检测在非小细胞肺癌中的临床意义 被引量:11

Clinical significance of EGFR gene mutation in pleural effusion cell blocks in non-small cell lung cancer
下载PDF
导出
摘要 目的探讨应用实时荧光定量PCR方法检测非小细胞肺癌阳性胸水细胞块EGFR突变的临床意义。方法收集具有组织标本作为对照的非小细胞肺癌阳性胸水60例,制作细胞块,提取DNA,应用实时荧光定量PCR法同时对细胞块和组织标本的EGFR第19外显子(19-Del)和21外显子(L858R)突变进行检测,分析细胞块与组织标本的EGFR突变率的差异。结果胸水细胞块中EGFR突变率为35%(21/60),其中19-Del突变11例,L858R突变9例,19-Del和L858R双突变1例;组织标本中EGFR突变率为36.7%(22/60),其中19-Del突变12例,L858R突变9例,19-Del和L858R双突变1例。两种标本的EGFR突变率差异无统计学意义(P>0.05);胸水细胞块EGFR突变类型与其对应的组织标本相一致。结论胸水细胞块与组织样本在EGFR基因突变上具有较高的一致性。 Objective To explore the clinical significance of EGFR mutations in positive pleural effusion cell block of non-small cell lung cancer by RT-PCR. Methods Sixty cases of biopsy tissue specimens and pleural effusion from non-small cell lung cancer patients were collected. Cell blocks of pleural effusion specimens were made. DNA was extracted to detect EGFR mutation in exon 19(19-Del) and exon 21( L858R) in biopsy tissue specimens and pleural effusion by RT-PCR. The mutation rate of EGFR was analyzed between pleural effusion and biopsy tissue specimens. Results The mutation rate of EGFR in pleural effusions was 35%(21/60),including 11 cases of 19-Del mutation,9 cases of L858 R mutation,and 1 case of 19-Del and L858 R double mutations. The mutation rate of EGFR in biopsy tissue specimens was 36. 7%(22/60),including 12 cases of 19-Del mutation,9 cases of L858 R mutation,and 1case of 19-Del and L858 R double mutations. The rates of EGFR mutation was not significantly different between the two types of specimens( P 〉 0. 05). The EGFR mutation types in pleural effusion were the same as that of the tissue specimen. Conclusion Pleural effusion cell block and biopsy tissue specimen show high consistency in EGFR mutation.
机构地区 解放军第
出处 《山西医科大学学报》 CAS 2017年第5期462-466,共5页 Journal of Shanxi Medical University
基金 福建漳州市科技局科研资助项目(z2011066) 南京军区医药卫生科研基金资助项目(10MA076) 解放军第175医院院内青年苗圃基金资助项目(16Y020)
关键词 肺癌 胸水 细胞学 EGFR基因 lung cancer pleural effusion cytology EGFR gene
  • 相关文献

参考文献9

二级参考文献80

  • 1田子强,刘俊峰,张少为,李保庆,王福顺,曹富民,张月峰.甲醛固定石蜡包埋组织中DNA的三种提取方法比较[J].基础医学与临床,2004,24(3):335-338. 被引量:6
  • 2HoUen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer:testing the lung cancer symptom scale (LCSS). Eur J Cancer, 1993, 29(A Suppl 1): 851-858.
  • 3Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med, 2002, 346(2): 92-98.
  • 4Parra HS, Cavina R,Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer, 2004, 91(2): 208-212.
  • 5Kim ES, Hirsh V, Mok T, et al. Getltinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase Ⅲ trial.Lancet, 2008, 372(9652): 1509-1818.
  • 6Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2): 123-132.
  • 7Mok TS, Wu YL,Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 1018-1020.
  • 8Chang GC, Tsai CM, Chen KC, et al. Predictive factors ofgefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol, 2006,1 (6): 520-525.
  • 9Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor recaptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in China's Mainland. J Thorac Oncol, 2007, 2(5): 430-439.
  • 10Reck M, Gatzemeier U. Benefit in lung cancer function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefiUnib. Lung Cancer, 2005, 50(1): 107-114.

共引文献59

同被引文献92

引证文献11

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部